Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT00150046
- Locations
- 🇨🇭
Basel Novartis Pharma AG, Basel, Switzerland
🇩🇪Novartis Investigational Site, Germany, Germany
Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 24
- Registration Number
- NCT00117702
- Locations
- 🇩🇪
Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus, Dresden, Germany
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00107237
- Locations
- 🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Duke Univaersity Medical Center, Durham, North Carolina, United States
Everolimus in Treating Patients With Stage IV Melanoma
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 53
- Registration Number
- NCT00098553
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸Rush-Copley Cancer Care Center, Aurora, Illinois, United States
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
- Conditions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00097968
- Locations
- 🇺🇸
Midstate Cardiology, Nashville, Tennessee, United States
🇺🇸University of Minnesota, Fairfield University Hospital, Minneapolis, Minnesota, United States
🇺🇸Columbia Presbyterian Medical Center, New York, New York, United States
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00096486
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00093639
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00085566
- Locations
- 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.